SNDX News and Press, Syndax Pharmaceuticals Inc. From 08/08/22

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call Presentation

Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update PR Newswire – On track to report topline data from revumenib and axatilimab pivotal programs starting in 1H23 – – Updated dat...

Syndax to Announce Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 8, 2022 PR Newswire WALTHAM, Mass. , Aug. 2, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical compa...

Syndax Pharmaceuticals (NASDAQ:SNDX) has appointed Keith Goldan as CFO, effective immediately. Goldan holds nearly 30 years of leadership and operational experience at several pharmaceutical, biotechnology. He served as CFO at Optinose most recently. At Syndax, Goldan will oversee corporate f...

Syndax Pharmaceuticals Announces Appointment of Keith A. Goldan as Chief Financial Officer PR Newswire WALTHAM, Mass. , June 13, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biop...

Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day PR Newswire WALTHAM, Mass. , May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical compan...

Syndax Pharmaceuticals, Inc. (SNDX) Q1 2022 Earnings Conference Call May 09, 2022 04:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael Metzger - Chief Executive Officer Briggs Morrison - President & Head, R&D Alex Nolte - Chief Accounting Officer Pet...

The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Syndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call Presentation

Syndax Pharmaceuticals press release (NASDAQ:SNDX): Q1 GAAP EPS of -$0.63. Total operating expenses of $36.85M. Research and development expenses of $30.02M. For Q2: Research and development expenses are expected to be $30M to $35M, and total operating expenses are expected to be $38M to $42M...

Syndax Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Business Update PR Newswire – Topline data from revumenib (SNDX-5613) and axatilimab pivotal programs expected starting in 1H23; Company remains on track for two FDA fi...